New York, USA – September 29, 2020 – As SARS-CoV-2 is still spreading in many countries around the world, the development of effective vaccines and drugs is still highly urgent. As a coronavirus with a positive-sense, single-stranded RNA, SARS-CoV-2 is challenging global scientists due to the high viral yields, short replication cycle, and high possibility of wrong replication of RNA virus genomes.
However, since its high structural conservation of the binding site, nucleoside analogue presents a great potential to be used for the treatment of SARS-CoV-2 infections. According to the advantages of nucleoside analogue, Creative Biolabs provides comprehensive R&D services of antiviral nucleoside analogues based on multiple action mechanisms, covering Ribavirin, Remdesivir, NHC, BCX4430, Gemcitabine Hydrochloride, 6-Azauridline, Mizoribine, and Acyclovir Fleximer.
Ribavirin, a guanosine analog with broad-spectrum antiviral activity, has long been used to treat the coronavirus family, but for SARS-CoV-2, the efficacy and safety still have to be further validated.
Creative Biolabs now provides a full range of standard assays to evaluate the antiviral efficiency of Ribavirin, including measuring the effects on the cytotoxicity, virus yield and infection rates of SARS-CoV-2s.
• Acyclovir Fleximer
In previous reports, a number of novel fleximers have been screened. Studies demonstrated that these fleximers can inhibit HCoV-NL63 and MERS-CoV replication in cell culture. Thus acyclovir fleximers for SARS-CoV-2 treatment worth further exploration.
As a forward-looking drug discovery service provider, Creative Biolabs can provide design, screening, synthesis and validation services of acyclovir fleximer to support clients’ drug discovery projects for SARS-CoV-2.
Remdesivir, a novel nucleotide analog prodrug, presents broad-spectrum antiviral activity, which has been recognized as a promising antiviral drug against a wide array of RNA viruses (including SRAS and MERS) infection in a series of animal models.
In response to the SARS-CoV-2 outbreak, Creative Biolabs provides the further assays of Remdesivir, as well as the development services of new antiviral drugs against SARS-CoV-2. The one-stop drug discovery platform for the drug development of SARS-CoV-2 covers the whole process of target identification and validation, hit identification, hit to lead, lead optimization, and IND-enabling.
The first-class antiviral drug discovery services also include broad-spectrum antiviral drug discovery (such as IFN-alpha and IFN-beta for SARS-CoV-2), protease inhibitors, antiviral peptide discovery, neutralizing antibodies, high-throughput screening (HTS), etc.
More information can be found on https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design (especially DNA vaccine and in Silico vaccine for SARS-CoV-2), preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.